Synergistic inhibitory activity of α- and β-LFA-1 peptides on LFA-1/ICAM-1 interaction

@article{YusufMakagiansar2001SynergisticIA,
  title={Synergistic inhibitory activity of $\alpha$- and $\beta$-LFA-1 peptides on LFA-1/ICAM-1 interaction},
  author={Helena Yusuf-Makagiansar and Irwan T. Makagiansar and Yongbo Hu and Teruna J. Siahaan},
  journal={Peptides},
  year={2001},
  volume={22},
  pages={1955-1962}
}
Abstract Interactions of cell-adhesion molecule LFA-1 and its ligand ICAM-1 play important roles during immune and inflammatory responses. Critical residues of LFA-1 for ICAM-1 binding are known to be in the I-domain of the α-subunit and the I-like domain of the β-subunit. On the basis of our previous work demonstrating the inhibitory activity of I-domain cyclic peptide cLAB.L on LFA-1/ICAM-1 interaction, here we have explored the activity of I-like-domain peptide LBE on the binding mechanism… Expand
Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides.
TLDR
Cyclic peptides derived from the parent IB peptide are designed that are inhibitors of ICAM-1/LFA-1-mediated T-cell adhesion to Caco-2 cell monolayers. Expand
Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors
This review describes the role of modulation of intracellular adhesion molecule-1 (ICAM-1)/leukocyte function-associated antigen-1 (LFA-1) interaction in controlling autoimmune diseases or inducingExpand
Mechanism of Binding and Internalization of ICAM-1-Derived Cyclic Peptides by LFA-1 on the Surface of T Cells: A Potential Method for Targeted Drug Delivery
TLDR
Cyclic ICAM-1-derived peptides (cIBL, cIBC, and cIBR) bind to the I-domain of LFA-1 and are internalized by L FA-1 receptors on the surface of T cells, suggesting that these peptides could be used to target and deliver drugs to the cytoplasmic domain of T Cells. Expand
Bind another day: The LFA-1/ICAM-1 interaction as therapeutic target
TLDR
The interaction between lymphocyte function-associated antigen-1 and its major ligand intercellular adhesion molecule-1 (ICAM-1 or CD54) has been extensively studied, leading to the development of therapeutic antibodies, peptides, and small inhibitory molecules. Expand
ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells.
TLDR
Sustained release of doxorubicin afforded by PLGA nanoparticles may enable cLABL-NP as a targeted, controlled release drug delivery system. Expand
Sequence Recognition of α‐LFA‐1‐derived Peptides by ICAM‐1 Cell Receptors: Inhibitors of T‐cell Adhesion
TLDR
This study determined the active region(s) of cLAB.L peptide by synthesizing and evaluating the biologic activity of hexapeptides in inhibiting T‐cell adhesion and designed more potent derivatives of cyclo(1,6)ITDGEA by utilizing structural and binding studies of the peptide to intercellular adhesion molecule‐1. Expand
cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells.
TLDR
N nanoparticles displaying the cIBR ligand may offer a useful targeted drug delivery system as an alternative treatment of inflammatory diseases involving transmigration of leukocytes. Expand
Cell adhesion molecules for targeted drug delivery.
TLDR
This review is focused on the utilization of cell adhesion peptides and receptors in specific targeted drug delivery, diagnostics, and tissue engineering. Expand
Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor
TLDR
PLP-BPI can effectively inhibit the disease severity and incidence of EAE with a lower possibility of inducing fatal anaphylaxis, and suggests that BPI-type molecules can be used to treat different autoimmune diseases in which antigenic epitopes have been identified. Expand
Controlling ligand surface density optimizes nanoparticle binding to ICAM-1.
During infection, pathogens utilize surface receptors to gain entry into intracellular compartments. Multiple receptor-ligand interactions that lead to pathogen internalization have been identifiedExpand
...
1
2
3
...

References

SHOWING 1-10 OF 29 REFERENCES
Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function
TLDR
Ten-amino acid peptides derived from the contact domains of LFA-1 and ICAM-1 were evaluated for their ability to interfere with intercellular adhesion by T cells and to inhibit a more biologic, mixed lymphocyte reaction. Expand
Peptides derived from ICAM-1 and LFA-1 modulate T cell adhesion and immune function in a mixed lymphocyte culture.
TLDR
The data suggest that these peptides or their derivatives may be useful as therapeutic modulators of LFA-1/ICAM-1 interaction during organ transplants. Expand
The native structure of intercellular adhesion molecule-1 (ICAM-1) is a dimer. Correlation with binding to LFA-1.
TLDR
Data suggest that ICAM-1 exists in its native membrane-bound and shed form as a non-covalent dimer, and that dimerization directly correlates with enhanced binding to LFA-1. Expand
Synthetic peptide analogs of intercellular adhesion molecule 1 (ICAM-1) inhibit HIV-1 replication in MT-2 cells.
TLDR
Investigation of the involvement of the ICAM-1 molecule by using selected synthetic peptides derived from the protein sequence found no significant inhibitory effects on RT activity, virus antigen production, and syncytium formation in HIV-1-infected MT-2 cells. Expand
Inhibition of Molt-4-endothelial adherence by synthetic peptides from the sequence of ICAM-1.
TLDR
Lymphocyte-endothelial interaction, and resulting inflammation, may be partially mediated by the association of ICAM-1 with LFA-1 at the specific molecular locations identified in this study. Expand
Mapping the Intercellular Adhesion Molecule-1 and -2 Binding Site on the Inserted Domain of Leukocyte Function-associated Antigen-1*
TLDR
Using mutagenic analysis of the inserted domain of the α-chain of the leukocyte function-associated antigen-1, a model of the interface between the LFA-1 I-domain and residues in the first domain of ICAM-1 that have been shown to be critical for this interaction is generated. Expand
The second domain of intercellular adhesion molecule-1 (ICAM-1) maintains the structural integrity of the leucocyte function-associated antigen-1 (LFA-1) ligand-binding site in the first domain.
TLDR
The data suggest that the second domain of ICAM-1 has a role in maintaining the structure of the LFA-1 ligand-binding site in the first domain but does not appear to have a direct role in ligand binding. Expand
A Binding Interface on the I Domain of Lymphocyte Function-associated Antigen-1 (LFA-1) Required for Specific Interaction with Intercellular Adhesion Molecule 1 (ICAM-1) (*)
TLDR
Using human/mouse LFA-1 α subunit chimeras, regions required for binding to ICAM-1 N-terminal to amino acid (aa) residue 359 are mapped and residues are shown to be located on the surface of the I domain surrounding the site to which Mg is chelated, and define a ligand binding interface. Expand
Binding and internalization of an ICAM-1 peptide by the surface receptors of T cells.
  • R. N. Gürsoy, T. Siahaan
  • Chemistry, Medicine
  • The journal of peptide research : official journal of the American Peptide Society
  • 1999
TLDR
The results show that FITC-cIBR binds to two populations of T cells with different affinities; population 1 has high cell numbers but low affinity, and population 2 has high binding affinity but low cell numbers. Expand
Role of ligands in the activation of LFA‐1
TLDR
These studies not only confirm that LFA‐1 exists in distinct ICAM‐specific activation states, but also demonstrate thatICAM‐1 plays a role in the activation of L FA‐1 binding to IC AM‐3. Expand
...
1
2
3
...